MEISi-1
Based on 1 Customer Validation
MEISi-1 is a small-molecule inhibitor targeting the homeodomain of the MEIS1 protein. MEISi-1 significantly inhibits the activity of luciferase reporter genes containing MEIS binding sites (TGACAG), and induces the self-renewal of a key type of mouse and human hematopoietic stem cells (HSC) both in vitro and in vivo. MEISi-1 promotes cardiomyocyte proliferation and cytokinesis, reduces cardiac fibroblast proliferation, and upregulates the expression of cardiomyocyte-specific genes. MEISi-1 can be used in research on hematological diseases, cardiac regeneration and cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.16%
- CAS 番号: 446306-43-0
- 分子式: C24H24N2O3
- 分子量:388.46
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Bioactive Compound Library Max
HY-L181
-
Anti-Aging Compound Library Mini
HY-L034M
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
生物活性
MEISi-1 (0.1-10 μM; 72 h) increases the proliferative capacity (up to 2.5-fold) and cytokinesis level (up to 2-fold) of neonatal rat ventricular cardiomyocytes[1].
MEISi-1 (5 μM; 72 h) reduces the viability/proliferative capacity of primary cardiac fibroblasts from adult mice[1].
MEISi-1 (10 nM-5 μM; 72 h) does not reduce the viability of human induced pluripotent stem cells (ATCC ACS-1026)[1].
MEISi-1 (5 μM; 18 days) upregulates pluripotency and cardiac mesoderm markers, increases the expression of the early cardiac marker Nkx2.5, decreases the expression of the late cardiac marker TNNT2, and inhibits the differentiation-associated upregulation of Meis1/2 expression in human induced pluripotent stem cells undergoing cardiomyocyte differentiation[1].
MEISi-1 (100 nM-5 μM; 3 days) upregulates the mesoderm marker Brachyury, the cardiac mesoderm marker GATA4, and the cardiac markers Nkx2.5 and TNNT2 during the cardiac mesoderm differentiation stage of human induced pluripotent stem cells, but does not alter the expression of ISL1[1].
MEISi-1 (0.1-10 μM; 7 days) significantly expands total hematopoietic cells from human umbilical cord blood and enriches CD34+, CD133+ and ALDHbr hematopoietic stem and progenitor cells in vitro[2].
MEISi-1 (0.1-10 μM; 7 days) significantly enriches multiple subsets of human mPB HSPCs in vitro, including the primitive CD34+CD38− cell population[2].
MEISi-1 (0.1-10 μM; 3 days) exerts no significant effect on the proliferation of human AD-MSCs or human HUVECs in vitro[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human induced pluripotent stem cells (hiPSCs) undergoing cardiac differentiation
-
Concentration:5 μM
-
Incubation Time:18 days
-
Result:Upregulated pluripotency markers TERT (2-fold), OCT4 (5-fold), KLF4 (6-fold), and SOX2 (10-fold).
Upregulated cardiac mesoderm markers ISL1 (60-fold) and Brachyury (70-fold).
Upregulated early cardiac marker Nkx2.5 (15-fold).
Downregulated late cardiac marker TNNT2 (6-fold).
Upregulated Meis1 (16-fold) and Meis2 (47-fold), representing a significant reduction in their upregulation compared to untreated differentiating cells.
-
Cell Line:human induced pluripotent stem cells (hiPSCs) undergoing cardiac differentiation to cardiac mesoderm
-
Concentration:100 nM, 1 μM, 2.5 μM, 5 μM
-
Incubation Time:3 days
-
Result:Had no significant effect on ISL1 expression.
Upregulated Brachyury expression, most notably at 5 μM, reaching ~2.5-fold relative to control.
Upregulated GATA4 expression, most notably at 5 μM, reaching ~6-fold relative to control.
Upregulated early cardiac marker Nkx2.5 expression, most notably at 2.5 μM, reaching ~30-fold relative to control.
Upregulated late cardiac marker TNNT2 expression, most notably at 2.5 μM, reaching ~16-fold relative to control.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (4-6 weeks old)[2]
-
Dosage:1 µM
-
Administration:i.p.; 3 total doses on day 1, day 4, day 7
-
Result:Increased the percentage of c-Kit+ cells to ~7%.
Increased the percentage of Sca-1+ cells to ~7%.
Increased the percentage of CD150+ cells to ~1.9%.
Increased the percentage of LSK HSPCs to ~1.6%.
Increased the percentage of LSKCD34low HSCs to ~0.8%.
Increased the percentage of LSKCD150+CD48− HSCs to ~0.2%.
Downregulated mRNA expression of Meis1, Hif-2α, p16, p19, and p19ARF in bone marrow cells.
化学情報
-
CAS 番号 446306-43-0
-
性状 Solid
-
分子量 388.46
-
分子式 C24H24N2O3
-
Color White to off-white
-
SMILES
O=C(NC1=CC=CC(C)=C1C)C2=CC=C(OCC(NCC3=CC=CC=C3)=O)C=C2
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
DMSO : 175 mg/mL (450.50 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (276 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Mammadova A, et al. Mechanistic insights into cardiac regeneration and protection through MEIS inhibition. Turkish journal of biology = Turk biyoloji dergisi. 2024;48(6):414-431. [Content Brief]
[2]. Turan RD, et al. Development of Small Molecule MEIS Inhibitors that modulate HSC activity. Scientific reports. 2020 May 14;10(1):7994. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5743 mL | 12.8713 mL | 25.7427 mL | 64.3567 mL |
| 5 mM | 0.5149 mL | 2.5743 mL | 5.1485 mL | 12.8713 mL | |
| 10 mM | 0.2574 mL | 1.2871 mL | 2.5743 mL | 6.4357 mL | |
| 15 mM | 0.1716 mL | 0.8581 mL | 1.7162 mL | 4.2904 mL | |
| 20 mM | 0.1287 mL | 0.6436 mL | 1.2871 mL | 3.2178 mL | |
| 25 mM | 0.1030 mL | 0.5149 mL | 1.0297 mL | 2.5743 mL | |
| 30 mM | 0.0858 mL | 0.4290 mL | 0.8581 mL | 2.1452 mL | |
| 40 mM | 0.0644 mL | 0.3218 mL | 0.6436 mL | 1.6089 mL | |
| 50 mM | 0.0515 mL | 0.2574 mL | 0.5149 mL | 1.2871 mL | |
| 60 mM | 0.0429 mL | 0.2145 mL | 0.4290 mL | 1.0726 mL | |
| 80 mM | 0.0322 mL | 0.1609 mL | 0.3218 mL | 0.8045 mL | |
| 100 mM | 0.0257 mL | 0.1287 mL | 0.2574 mL | 0.6436 mL |
MEISi-1 関連分類
HY-134258 関連分類
Powered by Bioz